Ontario Court of Appeal: Apotex not entitled to damages for generic drug's delayed market entry

By Karunjit Singh ( March 13, 2025, 5:53 PM EDT) -- The Ontario Court of Appeal has ruled that generic drugmaker Apotex is not entitled to damages for the delayed entry of a generic drug that was based on a patent held by Eli Lilly, despite the fact that the patent was invalidated in a separate action by Teva....
LexisNexis® Research Solutions

Documents

Related Sections